MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer

MolDX covers prognostic and predictive molecular diagnostic tests for beneficiaries with actively managed bladder cancer when the test is indicated for the patient population, demonstrates analytical and clinical validity and utility, completes a MolDX technical assessment, and either informs choice among multiple treatment intensities or predicts response to specific therapies per recognized society guidelines. NGS tests must meet NCD 90.2 (advanced cancer, planned treatment, no prior identical testing), and only one test per genomic content is allowed pre-therapy unless a second, different-content test independently meets all criteria.

"Beneficiary has a diagnosis of bladder cancer and is being actively managed for bladder cancer."

Sign up to see full coverage criteria, indications, and limitations.